JP7640466B2 - Ｃｄ４０活性化特性を有する組換えタンパク質 - Google Patents

Ｃｄ４０活性化特性を有する組換えタンパク質 Download PDF

Info

Publication number
JP7640466B2
JP7640466B2 JP2021558528A JP2021558528A JP7640466B2 JP 7640466 B2 JP7640466 B2 JP 7640466B2 JP 2021558528 A JP2021558528 A JP 2021558528A JP 2021558528 A JP2021558528 A JP 2021558528A JP 7640466 B2 JP7640466 B2 JP 7640466B2
Authority
JP
Japan
Prior art keywords
seq
cd40l
antibody
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021558528A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527506A (ja
JP2022527506A5 (https=
Inventor
イヴ・レヴィ
ヴァレンティナ・セグリア
サンドラ・ズラウスキ
ジェラード・ズラウスキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Baylor Research Institute
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Baylor Research Institute filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2022527506A publication Critical patent/JP2022527506A/ja
Publication of JP2022527506A5 publication Critical patent/JP2022527506A5/ja
Application granted granted Critical
Publication of JP7640466B2 publication Critical patent/JP7640466B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021558528A 2019-03-27 2020-03-26 Ｃｄ４０活性化特性を有する組換えタンパク質 Active JP7640466B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19305389.9 2019-03-27
EP19305389 2019-03-27
EP19213891 2019-12-05
EP19213891.5 2019-12-05
PCT/EP2020/058597 WO2020193718A1 (en) 2019-03-27 2020-03-26 Recombinant proteins with cd40 activating properties

Publications (3)

Publication Number Publication Date
JP2022527506A JP2022527506A (ja) 2022-06-02
JP2022527506A5 JP2022527506A5 (https=) 2023-04-03
JP7640466B2 true JP7640466B2 (ja) 2025-03-05

Family

ID=69846497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021558528A Active JP7640466B2 (ja) 2019-03-27 2020-03-26 Ｃｄ４０活性化特性を有する組換えタンパク質

Country Status (6)

Country Link
US (1) US12576147B2 (https=)
EP (1) EP3947454A1 (https=)
JP (1) JP7640466B2 (https=)
KR (1) KR20220004985A (https=)
CN (1) CN113811547B (https=)
WO (1) WO2020193718A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
US11117936B2 (en) * 2017-11-10 2021-09-14 University of Pittsburg—Of the Commonwealth System of Higher Education Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
GB202008003D0 (en) * 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
EP4267176A1 (en) * 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
US20240101693A1 (en) * 2021-01-21 2024-03-28 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
JP2024521082A (ja) * 2021-05-18 2024-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション アミロイド障害を処置するための抗体－ペプチド融合タンパク質
WO2023088876A1 (en) * 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators
US20250277016A1 (en) * 2022-04-22 2025-09-04 The United States Government As Represented By The Department Of Veterans Affairs Antibodies and methods of use
EP4658303A1 (en) * 2023-02-02 2025-12-10 Institut National de la Santé et de la Recherche Médicale Anti-tuberculosis vaccine targeting selected mycobacterium tuberculosis protective antigens to dendritic cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533118A (ja) 1998-12-29 2002-10-08 ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ Ｔ細胞レセプター使用を改変するためのｃｄ４０係合の使用
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
JP2018515072A (ja) 2015-05-04 2018-06-14 アポジェニックス アーゲー 単鎖ｃｄ４０受容体アゴニストタンパク質

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
WO2001026608A2 (en) * 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
CA2399790C (en) * 2000-02-02 2012-10-30 Ralph A. Tripp Cd40 ligand adjuvant for respiratory syncytial virus
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
ES2400660T3 (es) * 2005-11-01 2013-04-11 Novartis Ag Usos de anticuerpos anti-CD40
EP1951862B1 (en) * 2005-11-07 2013-07-24 MicroVAX, LLC Cd40 ligand fusion protein vaccine
AR060487A1 (es) * 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
CN101657464A (zh) 2007-02-02 2010-02-24 贝勒研究院 与靶向人源化单克隆抗体复合的多变量抗原
ES2685823T3 (es) * 2008-07-16 2018-10-11 Baylor Research Institute Anticuerpos antagonistas anti-CD40
AU2010222942B2 (en) * 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
CN102770457A (zh) 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
DK2406289T3 (en) 2009-03-10 2017-05-01 Baylor Res Inst ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
KR20130108295A (ko) 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
WO2014121099A1 (en) * 2013-01-31 2014-08-07 Thomas Jefferson University Agonist fusion protein for cd40 ox40 and uses thereof
AU2014233114B2 (en) * 2013-03-15 2018-03-08 Richard S. Kornbluth Composition comprised of antigen linked to a TNF SuperFamily ligand
CN120939216A (zh) 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
MA41460A (fr) * 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
DE112016006501T5 (de) 2016-02-26 2018-11-29 Mitsubishi Electric Corp. Zündspulenvorrichtung für Verbrennungsmotor
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
TWI761348B (zh) 2016-05-27 2022-04-21 美商艾伯維生物醫療股份有限公司 抗cd40抗體及其用途
US10610585B2 (en) * 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
JP7676150B2 (ja) * 2018-06-01 2025-05-14 サノフイ Ｂ型肝炎ウイルス感染を治療するための併用療法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002533118A (ja) 1998-12-29 2002-10-08 ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ Ｔ細胞レセプター使用を改変するためのｃｄ４０係合の使用
JP2018515072A (ja) 2015-05-04 2018-06-14 アポジェニックス アーゲー 単鎖ｃｄ４０受容体アゴニストタンパク質
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Immunologic Research，2013年，Vol.57，p.303-310，doi:10.1007/s12026-013-8443-6

Also Published As

Publication number Publication date
KR20220004985A (ko) 2022-01-12
US20220175920A1 (en) 2022-06-09
JP2022527506A (ja) 2022-06-02
CN113811547A (zh) 2021-12-17
CN113811547B (zh) 2024-06-25
EP3947454A1 (en) 2022-02-09
US12576147B2 (en) 2026-03-17
WO2020193718A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7640466B2 (ja) Ｃｄ４０活性化特性を有する組換えタンパク質
US10844121B2 (en) Antibodies binding LAG-3 and uses thereof
JP7038064B2 (ja) ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
ES2982109T3 (es) Anticuerpos anti PD-1, PD-L1 y PD-L2 humanos y usos de los mismos
CN109641037B (zh) 抗psma抗体及其用途
CN110396129B (zh) 人源化cd19抗原结合单链抗体及其嵌合抗原受体、免疫细胞和应用
CN115057931B (zh) 抗人lag-3抗体及其用途
US20120213771A1 (en) Antibodies that bind human cd27 and uses thereof
JP2016530278A (ja) Ｇｉｔｒ抗原結合タンパク質
WO2018113258A1 (zh) 抗pd-1抗体及其用途
MX2011009439A (es) Vacunas con especificidad de objetivo hacia celula presentadora de antigeno.
US20240010721A1 (en) Ror1-targeting antibody or antigen-binding fragment thereof, preparation method therefor, and application thereof
TWI910146B (zh) 抗flt3抗體及組合物
JP2023513200A (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
JP2026062799A (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
CN114981301A (zh) Pd1和vegfr2双结合剂
WO2022150740A1 (en) Cross-reactive antibodies recognizing the coronavirus spike s2 domain
JP2005510201A (ja) Ｈｉｖ−１に対する中和ヒトモノクローナル抗体、それらの産生および使用
US11807683B2 (en) Antibody binding TIM-3 and use thereof
TW202132348A (zh) 抗cd40抗體及組合物
US20230183366A1 (en) Recombinant proteins with ox40 activating properties
HK40076079B (zh) 抗人lag-3抗体及其用途
HK40040207A (en) Antibody binding tim-3 and use thereof
HK40040207B (en) Antibody binding tim-3 and use thereof
NZ789986A (en) Antibodies against tim3 and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250220

R150 Certificate of patent or registration of utility model

Ref document number: 7640466

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150